Nicotine neuroprotection against nigrostriatal damage: importance of the animal model

Nicotinic Acetylcholine Receptors and Nicotinic Cholinergic Mechanisms of the Central Nervous System

2006 • 1,130 citations

Parkinson's disease

2004 • 1,103 citations

Classic toxin-induced animal models of Parkinson?s disease: 6-OHDA and MPTP

2004 • 755 citations

Toxin-induced models of Parkinson’s disease

2005 • 722 citations

Inhibition of monoamine oxidase B in the brains of smokers

1996 • 666 citations

Diagnosis and treatment of Parkinson disease: molecules to medicine

2006 • 622 citations

Nicotinic acetylcholine receptors and the regulation of neuronal signalling

2004 • 584 citations

Cholinergic interneuron characteristics and nicotinic properties in the striatum

2002 • 428 citations

Cigarette smoking and protection from Parkinson's disease

1995 • 372 citations

Desensitization of nicotinic ACh receptors: shaping cholinergic signaling

2005 • 342 citations

Challenges in Parkinson's disease: restoration of the nigrostriatal dopamine system is not enough

2004 • 334 citations

Smoking, nicotine and Parkinson's disease

2004 • 309 citations

Neuroprotective agents for clinical trials in Parkinson’s disease

2003 • 262 citations

Nicotine addiction: the possible role of functional upregulation

2002 • 247 citations

Dose‐related neuroprotective effects of chronic nicotine in 6‐hydroxydopamine treated rats, and loss of neuroprotection in α4 nicotinic receptor subunit knockout mice

2001 • 182 citations

The Role of Neuronal Nicotinic Acetylcholine Receptors in Acute and Chronic Neurodegeneration

2002 • 181 citations

Smoking and Parkinson's disease: Systematic review of prospective studies

2004 • 180 citations

The Scientific Basis for the Current Treatment of Parkinson's Disease

2004 • 170 citations

Nicotinic receptor agonists as neuroprotective/neurotrophic drugs. Progress in molecular mechanisms

2006 • 155 citations

Nicotine prevents striatal dopamine loss produced by 6-hydroxydopamine lesion in the substantia nigra11Published on the World Wide Web on 1 December 2000.

2001 • 131 citations

Effects of (−)-nicotine and (−)-cotinine on 6-hydroxydopamine-induced oxidative stress and neurotoxicity: relevance for Parkinson’s disease

2002 • 122 citations

Chronic oral nicotine treatment protects against striatal degeneration in MPTP‐treated primates

2006 • 121 citations

Chronic nicotine treatment counteracts the disappearance of tyrosine-hydroxylase-immunoreactive nerve cell bodies, dendrites and terminals in the mesostriatal dopamine system of the male rat after partial hemitransection

1988 • 115 citations

New ideas on the origin of l-dopa-induced dyskinesias: age, genes and neural plasticity

2005 • 109 citations

Cigarette smoke and nicotine protect dopaminergic neurons against the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Parkinsonian toxin

2003 • 98 citations

Animal models of Parkinson’s disease in rodents induced by toxins: an update

2003 • 92 citations

Differential effects of acute and chronic nicotine treatment on MPTP-(1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) induced degeneration of nigrostriatal dopamine neurons in the black mouse

1992 • 85 citations

Neuroprotective strategies for Parkinson's disease: conceptual limits of animal models and clinical trials

2004 • 84 citations

Effects of nicotine on hydroxyl free radical formation in vitro and on MPTP-induced neurotoxicity in vivo

1998 • 75 citations

Chronic Oral Nicotine Normalizes Dopaminergic Function and Synaptic Plasticity in 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Lesioned Primates

2006 • 72 citations

Stimulation of non-α7 nicotinic receptors partially protects dopaminergic neurons from 1-methyl-4-phenylpyridinium-induced toxicity in culture

2002 • 68 citations

Nicotine and neurodegeneration in ageing

2002 • 68 citations

Attenuation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity by tobacco smoke

1990 • 58 citations

Nicotine partially protects against paraquat‐induced nigrostriatal damage in mice; link to α6β2* nAChRs

2006 • 50 citations

Nicotine Enhances 1‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine Neurotoxicity

1992 • 50 citations

1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity: partial protection against striato-nigral dopamine depletion in C57BL/6J mice by cigarette smoke exposure and by β-naphthoflavone-pretreatment

1991 • 47 citations

Nicotine, but neither the α4β2 ligand RJR2403 nor an α7 nAChR subtype selective agonist, protects against a partial 6-hydroxydopamine lesion of the rat median forebrain bundle

2006 • 44 citations

Enhanced MPTP neurotoxicity after treatment with isoflurophate or cholinergic agonists.

1994 • 37 citations

EFFECTS OF NICOTINE ON 1-METHYL-4-PHENYL-1,2,5,6-TETRAHYDROPYRIDINE-INDUCED DEPRESSION OF STRIATAL DOPAMINE CONTENT AND SPONTANEOUS LOCOMOTOR ACTIVITY IN C57 BLACK MICE

1998 • 33 citations

Exposure to cigarette smoke does not decrease the neurotoxicity of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice

1987 • 26 citations

Effect of chronic oral nicotine on dopaminergic function in the MPTP-treated mouse

1988 • 25 citations

Partial Recovery of Striatal Nicotinic Receptors in 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-Lesioned Monkeys with Chronic Oral Nicotine

2006 • 25 citations

Presynaptic involvement in the nicotine prevention of the dopamine loss provoked by 6-OHDA administration in the substantia nigra

2002 • 18 citations

The Effect of Chronic Nicotine Treatment on 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Induced Degeneration of Nigrostriatal Dopamine Neurons in the Black Mouse

1991 • 8 citations